Founder and Executive Chairman of the Board to
Advance Quantum-Si’s Protein Sequencing Technology and
Commercialization Strategy
Feb. 14, 2022--Quantum-Si Incorporated (Nasdaq: QSI)
(“Quantum-Si,” “QSI” or the “Company”), a life sciences company
commercializing single molecule protein sequencing, today announced
the appointment of Dr. Jonathan Rothberg, Founder and Executive
Chairman of Quantum Si’s Board of Directors, as Interim CEO. Dr.
Rothberg succeeds John Stark, effective February 8, 2022, while the
Company’s Board of Directors commences a search process to identify
a long-term CEO.
“Quantum-Si’s first-of-its-kind next generation protein
sequencing has the potential to impact immunology, diagnostics and
drug development in the same way that next generation DNA
sequencing impacted oncology and precision medicine,” said Dr.
Jonathan Rothberg. “We remain committed to the commercial launch of
our groundbreaking technology in 2022. Two years into a global
pandemic, this technology is more important than ever. We need to
fully understand our immune response to COVID-19 as well as other
pathogens.”
Dr. Rothberg is a prolific inventor, scientist and entrepreneur
who has successfully founded and launched multiple life science and
medical device companies, including 454 Life Sciences, AI
Therapeutics, Butterfly Network, CuraGen, Detect, Hyperfine, Ion
Torrent, Liminal Sciences, Protein Evolution, RainDance
Technologies, Tesseract Health and Quantum-Si. In 2006, Dr.
Rothberg was awarded the National Medal of Technology and
Innovation by President Barack Obama for pioneering high-speed next
generation DNA sequencing and ushering in the age of precision
medicine.
Quantum-Si will report fourth quarter and full year 2021
financial results and provide a business update after market close
on Monday, February 28, 2022.
Dr. Jonathan Rothberg’s Interim CEO Appointment Call
Quantum-Si will host a conference call to discuss the appointment
of Dr. Jonathan Rothberg as Interim CEO today, February 14, 2022,
at 5:00 PM Eastern Time. Individuals interested in listening to the
conference call may do so by dialing (844) 200-6205 for domestic
callers or (929) 526-1599 for international callers (no Conference
ID is needed). A live and archived webcast of the event will be
available on the Investors section of the Quantum-Si website under
Events & Presentations.
About Jonathan Rothberg, Ph.D. Jonathan M. Rothberg,
Ph.D., is the founder of Quantum-Si and has served as the Executive
Chairman of Quantum-Si’s board of directors since December 2015. He
previously served as Quantum-Si’s CEO from December 2015 to
November 2020. Dr. Rothberg is a scientist and entrepreneur who was
awarded the National Medal of Technology and Innovation, the
nation’s highest honor for technological achievement, by President
Barack Obama for inventing and commercializing high-speed DNA
sequencing. Dr. Rothberg is the founder of the 4Catalyzer medical
technology incubator and the founder and Chairman of its companies:
Quantum-Si, Butterfly Network, Inc., AI Therapeutics, Inc.,
Hyperfine Research, Inc., Tesseract Health, Inc., Liminal Sciences,
Inc., and Detect, Inc. and Protein Engineering, Inc. These
companies focus on using inflection points in medicine, such as
deep learning, next-generation sequencing, and the silicon supply
chain, to address global healthcare challenges. Dr. Rothberg
previously founded and served as Chairman, Chief Executive Officer,
and Chief Technology Officer of Ion Torrent Systems, Inc. from 2007
to 2010, and founded and served as Chairman and Chief Executive
Officer of RainDance Technologies, Inc. from 2004 to 2009. From
1999 to 2007, Dr. Rothberg co-founded and served as Chairman of
ClariFI, Inc., and from 1999 to 2006, he founded and served as
Chairman, Chief Executive Officer and Chief Technology Officer of
454 Life Sciences Corporation. With 454 Life Sciences, Dr. Rothberg
brought to market the first new way to sequence genomes since
Sanger and Gilbert won the Nobel Prize for their method in 1980.
With 454’s technology, Dr. Rothberg sequenced the first individual
human genome, and with Svante Paabo he initiated the first
large-scale effort to sequence ancient DNA (The Neanderthal Genome
Project). Prior to 454 Life Sciences, Dr. Rothberg founded and
served as Chairman and Chief Executive Officer of CuraGen
Corporation from 1993 to 2004. His contributions to the field of
genome sequencing include the first non-bacterial cloning method
(cloning by limited dilution) and the first massively parallel DNA
sequencing method (parallel sequencing by synthesis on a single
substrate), concepts that have formed the basis for all subsequent
next generation sequencing technologies. Dr. Rothberg is an Ernst
and Young Entrepreneur of the Year, is the recipient of The Wall
Street Journal’s First Gold Medal for Innovation, SXSW Best in
Show, Nature Methods First Method of the Year Award, the
Connecticut Medal of Technology, the DGKL Biochemical Analysis
Prize, and an Honorary Doctorate of Science from Mount Sinai. Dr.
Rothberg is a member of the National Academy of Engineering, the
Connecticut Academy of Science and Engineering, served as a trustee
of Carnegie Mellon University and is an Adjunct Professor of
Genetics at Yale University. Dr. Rothberg received his Ph.D.,
M.Phil. and M.S. in biology from Yale University and his B.S. in
chemical engineering from Carnegie Mellon University.
About Quantum-Si Incorporated Quantum-Si is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable single molecule
next-generation protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
www.quantum-si.com.
Forward Looking Statements This press release includes
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the United States Private Securities
Litigation Reform Act of 1995. The actual results of the Company
may differ from its expectations, estimates, and projections and,
consequently, you should not rely on these forward-looking
statements as predictions of future events. Words such as "expect,"
"estimate," "project," "budget," "forecast," "anticipate,"
"intend," "plan," "may," "will," "could," "should," "believes,"
"predicts," "potential," "continue," and similar expressions (or
the negative versions of such words or expressions) are intended to
identify such forward-looking statements. These forward-looking
statements include, without limitation, the Company's expectations
with respect to future performance and development of products and
services. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from those discussed in the forward-looking
statements. Most of these factors are outside the Company's control
and are difficult to predict. Factors that may cause such
differences include, but are not limited to: the impact of COVID-19
on the Company's business; the inability to maintain the listing of
the Company's shares of Class A common stock on The Nasdaq Stock
Market; the ability to recognize the anticipated benefits of the
recently completed business combination, which may be affected by,
among other things, competition and the ability of the Company to
grow and manage growth profitably and retain its key employees;
changes in applicable laws or regulations; the ability of the
Company to raise financing in the future; the success, cost and
timing of the Company's product development activities; the
potential attributes and benefits of the Company's products and
services; the Company's ability to obtain and maintain regulatory
approval for its products, and any related restrictions and
limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development of products and services that the Company is
developing; the size and growth potential of the markets for the
Company's future products and services, and its ability to serve
those markets, either alone or in partnership with others; the
pricing of the Company's products and services following
anticipated commercial launch; the Company's estimates regarding
future expenses, future revenue, capital requirements and needs for
additional financing; the Company's financial performance; and
other risks and uncertainties indicated from time to time in the
proxy statement/prospectus relating to the business combination,
including those under "Risk Factors" therein, and in the Company's
other filings with the SEC. The Company cautions that the foregoing
list of factors is not exclusive. The Company cautions readers not
to place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220214005816/en/
Investors Juan Avendano Mike Cavanaugh
ir@quantum-si.com
Media Jon Yu QSI-PR@westwicke.com
Quality Systems (NASDAQ:QSII)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Quality Systems (NASDAQ:QSII)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
